LeonaBio Appoints Mark Kubik as Chief Business Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy LONA?
LeonaBio announced the appointment of Mark Kubik as Chief Business Officer. Kubik previously served as a strategic consultant to LeonaBio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LONA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LONA
Wall Street analysts forecast LONA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 9.680
Low
Averages
High
Current: 9.680
Low
Averages
High
About LONA
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LeonaBio Reports FY 2025 Financial Results
- Earnings Loss: LeonaBio reported a GAAP EPS of -$24.70 for FY 2025, indicating significant challenges in profitability that could negatively impact investor confidence and stock performance.
- Improved Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and investments totaled $88.3 million, a substantial increase from $51.3 million in 2024, suggesting enhanced financial management and increased operational flexibility for future endeavors.
- Reduced Operating Cash Flow: The net cash used in operations for FY 2025 was $45.7 million, a significant decrease from $97.2 million in 2024, reflecting progress in cost control and operational efficiency, potentially laying the groundwork for future profitability.
- Corporate Restructuring: LeonaBio is undergoing a name and ticker symbol change, a strategic move aimed at rebranding and attracting new investors, thereby enhancing market competitiveness and shareholder value.
See More
LEONABIO INC ANTICIPATES COMPLETION OF PHASE 3 LASOFOXIFENE TRIAL ENROLLMENT BY Q4 2026, WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2027
- Phase 3 Trial Expectations: Leonabiol is anticipating the completion of Phase 3 trials for its product by the second quarter of 2026.
- Topline Data Release: The company plans to release topline data from the trials in the second half of 2027.
See More
LeonaBio Secures License for Lasofoxifene Development Program
- Successful Financing: LeonaBio secured $90 million in private placement financing, with cash-exercisable warrants potentially providing an additional $146 million, which will robustly support the development of Lasofoxifene through key clinical and regulatory milestones, ensuring financial stability for the company.
- Clinical Trial Progress: The company expects to complete enrollment for the Phase 3 clinical trial of Lasofoxifene by Q4 2026, with topline data anticipated in the second half of 2027, offering a new treatment option for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, which holds significant market potential.
- Drug Development Strategy: As a novel selective estrogen receptor modulator, Lasofoxifene aims to target ESR1 mutations in metastatic breast cancer patients, potentially becoming the preferred second-line treatment and altering the standard of care in this field, enhancing the company's competitive position in the biopharmaceutical market.
- New Drug Candidate ATH-1105: LeonaBio plans to initiate a Phase 2 proof-of-concept study for ATH-1105 in ALS patients in the second half of 2026, demonstrating the company's diversified strategy and innovative capabilities in the neurodegenerative disease sector.
See More
LEONABIO INC: MIZUHO UPGRADES RATING TO OUTPERFORM AND INCREASES TARGET PRICE TO $10 FROM $4
Company Performance: Leonabi Inc. has reported a significant improvement in its performance, indicating positive growth and operational efficiency.
Target Price Increase: The company's target price has been raised to $10 from a previous $4, reflecting increased investor confidence and market expectations.
See More
LeonaBio Reports FY 2025 Financial Results
- Earnings Loss: LeonaBio reported a GAAP EPS of -$24.70 for FY 2025, indicating significant challenges in profitability that could negatively impact investor confidence and stock performance.
- Improved Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and investments totaled $88.3 million, a substantial increase from $51.3 million in 2024, suggesting enhanced financial management and increased operational flexibility for future endeavors.
- Reduced Operating Cash Flow: The net cash used in operations for FY 2025 was $45.7 million, a significant decrease from $97.2 million in 2024, reflecting progress in cost control and operational efficiency, potentially laying the groundwork for future profitability.
- Corporate Restructuring: LeonaBio is undergoing a name and ticker symbol change, a strategic move aimed at rebranding and attracting new investors, thereby enhancing market competitiveness and shareholder value.
See More
LEONABIO INC ANTICIPATES COMPLETION OF PHASE 3 LASOFOXIFENE TRIAL ENROLLMENT BY Q4 2026, WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2027
- Phase 3 Trial Expectations: Leonabiol is anticipating the completion of Phase 3 trials for its product by the second quarter of 2026.
- Topline Data Release: The company plans to release topline data from the trials in the second half of 2027.
See More
LeonaBio Secures License for Lasofoxifene Development Program
- Successful Financing: LeonaBio secured $90 million in private placement financing, with cash-exercisable warrants potentially providing an additional $146 million, which will robustly support the development of Lasofoxifene through key clinical and regulatory milestones, ensuring financial stability for the company.
- Clinical Trial Progress: The company expects to complete enrollment for the Phase 3 clinical trial of Lasofoxifene by Q4 2026, with topline data anticipated in the second half of 2027, offering a new treatment option for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, which holds significant market potential.
- Drug Development Strategy: As a novel selective estrogen receptor modulator, Lasofoxifene aims to target ESR1 mutations in metastatic breast cancer patients, potentially becoming the preferred second-line treatment and altering the standard of care in this field, enhancing the company's competitive position in the biopharmaceutical market.
- New Drug Candidate ATH-1105: LeonaBio plans to initiate a Phase 2 proof-of-concept study for ATH-1105 in ALS patients in the second half of 2026, demonstrating the company's diversified strategy and innovative capabilities in the neurodegenerative disease sector.
See More
LEONABIO INC: MIZUHO UPGRADES RATING TO OUTPERFORM AND INCREASES TARGET PRICE TO $10 FROM $4
Company Performance: Leonabi Inc. has reported a significant improvement in its performance, indicating positive growth and operational efficiency.
Target Price Increase: The company's target price has been raised to $10 from a previous $4, reflecting increased investor confidence and market expectations.
See More
